EP0721350A4 - Immunisation intracellulaire - Google Patents

Immunisation intracellulaire

Info

Publication number
EP0721350A4
EP0721350A4 EP94925693A EP94925693A EP0721350A4 EP 0721350 A4 EP0721350 A4 EP 0721350A4 EP 94925693 A EP94925693 A EP 94925693A EP 94925693 A EP94925693 A EP 94925693A EP 0721350 A4 EP0721350 A4 EP 0721350A4
Authority
EP
European Patent Office
Prior art keywords
intracellular immunization
immunization
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94925693A
Other languages
German (de)
English (en)
Other versions
EP0721350A1 (fr
Inventor
Lingxun Duan
Roger Pomerantz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of EP0721350A1 publication Critical patent/EP0721350A1/fr
Publication of EP0721350A4 publication Critical patent/EP0721350A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1072—Regulatory proteins, e.g. tat, rev, vpt
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Luminescent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP94925693A 1993-07-30 1994-07-28 Immunisation intracellulaire Withdrawn EP0721350A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99870 1987-09-22
US9987093A 1993-07-30 1993-07-30
PCT/US1994/008448 WO1995003832A1 (fr) 1993-07-30 1994-07-28 Immunisation intracellulaire

Publications (2)

Publication Number Publication Date
EP0721350A1 EP0721350A1 (fr) 1996-07-17
EP0721350A4 true EP0721350A4 (fr) 1999-08-11

Family

ID=22277017

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94925693A Withdrawn EP0721350A4 (fr) 1993-07-30 1994-07-28 Immunisation intracellulaire

Country Status (5)

Country Link
EP (1) EP0721350A4 (fr)
JP (1) JPH09500902A (fr)
AU (1) AU682206B2 (fr)
CA (1) CA2168349A1 (fr)
WO (1) WO1995003832A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010846A1 (fr) * 1995-09-18 1997-03-27 Intracel Corporation Anticorps monoclonaux neutralisants diriges contre le virus syncytial respiratoire
CA2383456C (fr) 1999-08-23 2016-06-07 Clive Wood Pd-1, recepteur de b7-4, et son utilisation
JP2003518942A (ja) 1999-12-30 2003-06-17 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 肝細胞成長、形質細胞分化、又はｔ細胞サブセットの活性を、ｘｂｐ−１活性の変調により変調することに関する方法及び組成物
JP2004533226A (ja) 2001-04-02 2004-11-04 ワイス Ｂ７−４に対するｐｄ−１、ａレセプター、およびその使用
EP2352841A2 (fr) 2008-09-23 2011-08-10 President and Fellows of Harvard College Sirt4 et utilisations de celui-ci
CN102264762B (zh) 2008-09-26 2018-03-27 达纳-法伯癌症研究公司 人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用
US20120020954A1 (en) 2009-03-30 2012-01-26 Anat Achiron Methods of predicting clinical course and treating multiple sclerosis
EP2483407A2 (fr) 2009-09-30 2012-08-08 President and Fellows of Harvard College Procédés de modulation de l'autophagie par la modulation de produits géniques renforçant l'autophagie
EP3168232B1 (fr) 2009-11-13 2021-09-29 Dana-Farber Cancer Institute, Inc. Compositions, kits et procédés de diagnostic, pronostic, suivi, traitement et modulation des troubles lymphoprolifératif post-transplantation et troubles de l'angiogenèse associés à l'hypoxie utilisant de la galectine-1
US9745589B2 (en) 2010-01-14 2017-08-29 Cornell University Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
WO2011132182A1 (fr) 2010-04-18 2011-10-27 Yeda Research And Development Co. Ltd. Molécules et méthodes d'utilisation de celles-ci pour le traitement des maladies associées aux ligands erbb/erbb
WO2012109238A2 (fr) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Procédés d'augmentation des réponses immunitaires à l'aide d'agents qui se lient directement à ire-1 et activent ire-1
US20130108618A1 (en) * 2011-10-28 2013-05-02 University Of Maryland METHODS AND COMPOSITIONS RELATED TO INTRACELLULAR NEUTRALIZATION BY IgG
WO2013134774A1 (fr) 2012-03-09 2013-09-12 Cornell University Modulation de la croissance du cancer du sein par modulation de l'activité de la xbp1
EP2879710B1 (fr) 2012-08-03 2019-11-13 Dana-Farber Cancer Institute, Inc. Indications médicales d'agents modulant l'activation des cellules immunitaires et méthodes de criblage
AU2014275166B2 (en) 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
US20160175401A1 (en) 2013-07-31 2016-06-23 Dana-Farber Cancer Institute Inc. Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
ES2724300T3 (es) 2013-09-25 2019-09-10 Univ Cornell Compuestos para inducir inmunidad antitumoral y métodos de lo mismo
WO2015048312A1 (fr) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Méthodes de traitement de cancers hématologiques
WO2015095868A1 (fr) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Méthodes et compositions permettant d'augmenter les taux d'anticorps protecteurs induits par des vaccins antipneumococciques polyosidiques
RU2017104284A (ru) 2014-07-15 2018-08-15 Йиссум Рисеч Девелопмент Компани Оф Зе Хебрю Юниверсити Оф Джерусалем Лтд. Выделенные полипептиды cd44 и их применение
JP6951246B2 (ja) 2014-11-05 2021-10-20 アネクソン，インコーポレーテッド ヒト化抗補体因子Ｃ１ｑ抗体及びその使用
WO2016079736A2 (fr) 2014-11-17 2016-05-26 Yeda Research And Development Co. Ltd. Procédés de traitement de maladies associées à une fonction mitochondriale
US11220545B2 (en) 2014-12-08 2022-01-11 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents
ES2805206T3 (es) 2015-03-10 2021-02-11 Univ Massachusetts Enfoque dirigido a GDF6 y a señalización de BMP para la terapia contra el melanoma
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
US20180161300A1 (en) 2015-05-11 2018-06-14 Yeda Research And Development Co., Ltd. Citrin inhibitors for the treatment of cancer
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
WO2017122203A1 (fr) 2016-01-11 2017-07-20 Technion Research & Development Foundation Limited Méthodes de détermination du pronostic de septicémie et traitement associé
BR112018067522A2 (pt) 2016-03-01 2019-02-05 Univ Of Rijeka Faculty Of Medicine anticorpos específicos para receptor de poliovírus humano (pvr)
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Treatment of stress disorders
WO2018216011A1 (fr) 2017-05-23 2018-11-29 Technion Research & Development Foundation Limited Agents inhibant la dimérisation de gads et leurs procédés d'utilisation
EP3962529A4 (fr) 2019-04-30 2023-11-01 Dana-Farber Cancer Institute, Inc. Méthodes de traitement du cancer à l'aide de combinaisons d'agents anti-cx3cr1 et d'agents de blocage de points de contrôle immunitaires
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
EP4096647A1 (fr) 2020-01-30 2022-12-07 Yeda Research and Development Co. Ltd Traitement d'une maladie hépatique aiguë à l'aide d'inhibiteurs de tlr-mik
IL279559A (en) 2020-12-17 2022-07-01 Yeda Res & Dev Controlling the ubiquitination process of mlkl for disease treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002610A1 (fr) * 1992-07-17 1994-02-03 Dana-Farber Cancer Institute Procede de liaison intracellulaire de molecules cibles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002610A1 (fr) * 1992-07-17 1994-02-03 Dana-Farber Cancer Institute Procede de liaison intracellulaire de molecules cibles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FEINBERG M B ET AL: "INTRACELLULAR IMMUNIZATION: TRANS-DOMINANT MUTANTS OF HIV GENE PRODUCTS AS TOOLS FOR THE STUDY AND INTERRUPTION OF VIRAL REPLICATION", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 8, no. 6, 1 June 1992 (1992-06-01), pages 1013 - 1022, XP000199752 *
MARASCO WA ET AL.: "Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody", PNAS, vol. 90, no. 16, 15 August 1993 (1993-08-15), pages 7889 - 93, XP000389696 *
See also references of WO9503832A1 *

Also Published As

Publication number Publication date
CA2168349A1 (fr) 1995-02-09
WO1995003832A1 (fr) 1995-02-09
EP0721350A1 (fr) 1996-07-17
AU682206B2 (en) 1997-09-25
AU7551394A (en) 1995-02-28
JPH09500902A (ja) 1997-01-28

Similar Documents

Publication Publication Date Title
EP0721350A4 (fr) Immunisation intracellulaire
GB9419218D0 (en) Methods
HU9601504D0 (en) Infuser
ZA947828B (en) Vaccines
DE59407177D1 (en) 2-fluorcycloyhexen-derivate
GB9325496D0 (en) Vaccines
GB2284506B (en) Thermostat
DE59408644D1 (en) Jacquardmaschine
GB9315306D0 (en) Methods
GB9322702D0 (en) Vaccines
GB9315351D0 (en) Methods
GB9315340D0 (en) Methods
DE59407310D1 (en) Phenylazotriazolopyridinfarbstoffe
GB9322808D0 (en) Vaccines
AU122479S (en) Label-printer
GB9315298D0 (en) Methods
GB9308780D0 (en) Methods
DE59403125D1 (en) Hohlleitermultiplexer/-demultiplexer
GB9315271D0 (en) Methods
GB9315341D0 (en) Methods
CA73639S (en) Handstamp
CA72257S (en) Floorstand
GB9323754D0 (en) Vaccine
ZA949128B (en) Vaccine
GB9306398D0 (en) Vaccines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960227

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19990624

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000508

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 48/00 A, 7C 12N 5/10 B, 7C 12N 15/13 B, 7C 12N 15/85 B, 7C 12N 15/86 B, 7A 61P 31/00 B, 7A 61P 33/00 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020703